Kane Biotech Announces Second Quarter 2025 Financial Results

Executive Summary

• Kane Biotech reported its second quarter 2025 financial results, showing a significant decline in revenue and a net loss, largely due to the sale of its previous animal health business (STEM) in Q2 2024 which skewed comparative figures.
• The company announced corporate governance updates, including the election of three new directors and the appointment of committee chairs, alongside operational updates regarding clinical data presentations and distributor changes.
• Key operational developments include the termination of an exclusive distribution agreement with ProgenaCare due to material breaches, the conversion of a $1 million insider loan into convertible debentures, and a notice of default from Prairies Economic Development Canada regarding outstanding payments.

Key Details

• Financial Highlights (Q2 2025 vs Q2 2024):
  • Total Revenue: $27,997 (vs. $620,437 in Q2 2024; comparative quarter included discontinued STEM Animal Health operations).
  • Gross Profit (Loss): $(45,526) (vs. $360,490 in Q2 2024).
  • Total Operating Expenses: $229,930 (vs. $1,463,397 in Q2 2024; reduction attributed to staff reduction, bonus reversals, and lower contract research expenditures).
  • Net Loss: $(348,541) (vs. $(1,215,996) in Q2 2024).
• Corporate Governance:
  • Three new directors elected at the Annual and Special Meeting on June 25, 2025: Ms. Anne Greven, Mr. Shameze Rampertab, and Dr. David Kideckel.
  • Three existing directors reelected: Mr. Philip Renaud, Dr. John Coleman, and Dr. Robert Huizinga.
  • Board Appointments (Aug 27, 2025): Mr. Rampertab appointed Chair of Audit and Compensation Committee; Ms. Greven appointed Chair of Governance & Nomination Committee; Dr. Coleman designated as Lead Independent Director.
• Operational & Strategic Updates:
  • Distribution Agreement: Terminated exclusive distribution agreement with ProgenaCare in Q2 2025 due to material breaches; discussions with new potential distributors are underway. US-labelled inventory has been moved to a US distribution center.
  • Financing: Converted an unsecured demand loan of $1 million from an insider into a $1 million principal amount 3% unsecured convertible debenture, due June 26, 2030.
  • Regulatory/Debt Issue: Received a notice of default from Prairies Economic Development Canada (PrairiesCan) regarding approximately $1.4 million outstanding on a $2.5 million Contribution Agreement; management is negotiating rescheduling of payments.
  • Clinical/Conference Activity: Presented preclinical data and clinical case observations at the NSWOCC 44th National Conference (May 21–25, 2025) and the SAWC Spring Conference (April 30–May 4, 2025). Completing a revyve clinical case series program with US wound care and burn specialists.
• Product Status: revyve® Antimicrobial Wound Gel and Spray are US FDA 510(k) cleared; revyve® Antimicrobial Wound Gel is Health Canada approved.

Notable Quotes

• “We are continuing to execute on the plan laid out at our last AGM. With key U.S. case series studies now underway, we anticipate generating compelling clinical evidence. Our presentations at recent wound care conferences generated meaningful engagement with both clinicians and potential partners, highlighting the market potential for our revyve portfolio. We are continuing our efforts to create meaningful distributor networks in the US. Corporately, the refreshing of our Board by the addition of three highly qualified directors strengthens our strategic capabilities at a pivotal stage of the company’s growth,” said Dr. Robert Huizinga, Interim CEO.